Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. It develops in the lining of the small tubes within the kidneys that filter blood and produce urine. Many cases are discovered incidentally during imaging tests performed for other medical reasons because early-stage RCC often causes no symptoms. Advances in surgery, targeted therapy, immunotherapy, and precision medicine have significantly improved treatment outcomes for many patients. Early diagnosis, individualized treatment planning, and regular follow-up with a multidisciplinary healthcare team are essential for achieving the best possible long-term results.
Renal cell carcinoma begins when kidney cells grow uncontrollably and form a tumor.
Several subtypes of RCC exist, including:
The specific subtype helps guide treatment decisions and prognosis.
Early-stage RCC may not cause noticeable symptoms. As the disease progresses, symptoms may include:
Many of these symptoms can also occur with non-cancerous kidney conditions.
Factors associated with an increased risk of RCC include:
Reducing modifiable risk factors may help lower the risk of developing kidney cancer.
Diagnosis typically involves imaging studies and laboratory testing.
Common diagnostic tests include:
Additional imaging may be performed to determine whether the cancer has spread.
Treatment depends on the size of the tumor, cancer stage, kidney function, and overall health.
Possible treatments include:
Treatment plans are individualized based on each person's condition.
Regular follow-up helps evaluate treatment success and detect recurrence.
Monitoring may include:
Follow-up schedules vary depending on the stage of the disease and the treatment received.
Healthy habits can support recovery and overall kidney health.
Recommendations often include:
Lifestyle measures complement medical treatment but do not replace it.
Prompt medical evaluation is recommended if symptoms include:
Early assessment may help identify recurrence or treatment-related complications.
Renal cell carcinoma is the most common form of kidney cancer in adults and is often highly treatable when detected early. Modern treatment options—including surgery, targeted therapy, immunotherapy, and minimally invasive procedures—have improved outcomes across many stages of the disease.